SCHEMBL3064332

SCHEMBL3064332

Cc1ccccc1-c1cccc2c1[CH]c1ccccc1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCUN1D1 Q96GG9 2/20 0.40
HTR7 P34969 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TSHR P16473 1/20 0.38
ACHE P22303 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 2/20 0.35
BRD4 O60885 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP3A4 P08684 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216981 0.89 ACHE (0.39) DCUN1D1HTR7NPC1RAB9ASMN1; SMN2
SCHEMBL2969427 0.79 ADORA3 (0.39) HTR7NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL6652271 0.78 HTR7 (0.35) HTR7NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL2966499 0.77 DCUN1D1 (0.31) DCUN1D1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL218438 0.77 TSHR (0.34) NPC1RAB9ASMN1; SMN2TSHRACHE
SCHEMBL2974242 0.76 PTPRC (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL2968620 0.76 ADRA1D (0.39)
SCHEMBL2959272 0.76
SCHEMBL216861 0.76 ALDH1A1 (0.44) DCUN1D1HTR7ALDH1A1HPGDTDP1
SCHEMBL197690 0.75 ACHE (0.64) DCUN1D1HTR7NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2045254-B1 RARE EARTH METAL COMPLEX, CATALYST FOR POLYMERIZATION AND PROCESS FOR PRODUCING POLYMER SUMITOMO CHEMICAL CO (JP) 2013-01-09 EP disclosed
US-7851569-B2 Rare earth metal complex, polymerization catalyst, and process for producing polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-12-14 US disclosed
US-20100261857-A1 OLEFIN/(METH)ACRYLATE BLOCK COPOLYMER AND METHOD FOR PRODUCING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-10-14 US disclosed
EP-2189483-A1 OLEFIN/(METH)ACRYLATE BLOCK COPOLYMER AND METHOD FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-05-26 EP disclosed
US-7615660-B2 Production process of alkoxy-titanium complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-10 US disclosed
US-20090253875-A1 RARE EARTH METAL COMPLEX, POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED 2009-10-08 US disclosed
EP-2045254-A1 RARE EARTH METAL COMPLEX, CATALYST FOR POLYMERIZATION AND PROCESS FOR PRODUCING POLYMER Sumitomo Chemical Company, Limited (JP) 2009-04-08 EP disclosed
US-20080306293-A1 Production Process of Alkoxy-Titanium Complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-12-11 US disclosed
EP-1845101-A1 METHOD FOR PRODUCING ALKOXYTITANIUM COMPLEX Sumitomo Chemical Company, Limited (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306293-A1 Production Process of Alkoxy-Titanium Complex ABL1, H1-10, ALK DCUN1D1 3770/4885HTR7 3707/4885NPC1 3893/4885
US-20090253875-A1 RARE EARTH METAL COMPLEX, POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYMER RPS27L, LAS1L, AGL DCUN1D1 2880/4885HTR7 4188/4885NPC1 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.